"uuid:ID","description","rationale","label","id","instanceType","name"
"99f94898-d9c7-4376-8700-060e1f58e740","The main design for the study","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","","StudyDesign_1","StudyDesign","Study Design 1"
